CTLA4 and pancreatic neoplasm: This synergy has been reported in mouse pancreatic cancer in vivo models, where chloroquine enhanced MHC-class-I expression and antitumor T-cell response under dual anti-PD-1/CTLA4 immunotherapy [28].